Jennifer Stevens
CIK: 0001982621
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
TriSalus Life Sciences, Inc.
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Oct 5, 2026TLSI
TriSalus Life Sciences, Inc.
Sale(S)Direct316 shares at avg. $4.39$1K - Mar 16, 2026TLSI
TriSalus Life Sciences, Inc.
Sale(S)Direct774 shares at avg. $4.12$3K - Mar 12, 2026TLSI
TriSalus Life Sciences, Inc.
Sale(S)Direct1.6K shares at avg. $4.09$6K - Mar 11, 2026TLSI
TriSalus Life Sciences, Inc.
Sale(S)Direct1.2K shares at avg. $4.13$5K - Nov 24, 2025TLSI
TriSalus Life Sciences, Inc.
Award(A)Direct50K shares- - May 19, 2025TLSI
TriSalus Life Sciences, Inc.
Award(A)Direct28.5K shares at avg. $5.18$147K - May 19, 2025TLSI
TriSalus Life Sciences, Inc.
Sale(S)Direct8.7K shares at avg. $5.18$45K - Feb 18, 2025TLSI
TriSalus Life Sciences, Inc.
Award(A)Direct14.5K shares- - Jan 27, 2025TLSI
TriSalus Life Sciences, Inc.
Award(A)Direct10.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 5, 2026 | TLSI TriSalus Life Sciences, Inc. | Sale(S) | 316 | $4.39 | $1,387 | Direct |
| Mar 16, 2026 | TLSI TriSalus Life Sciences, Inc. | Sale(S) | 774 | $4.12 | $3,189 | Direct |
| Mar 12, 2026 | TLSI TriSalus Life Sciences, Inc. | Sale(S) | 1,552 | $4.09 | $6,348 | Direct |
| Mar 11, 2026 | TLSI TriSalus Life Sciences, Inc. | Sale(S) | 1,204 | $4.13 | $4,973 | Direct |
| Nov 24, 2025 | TLSI TriSalus Life Sciences, Inc. | Award(A) | 50,000 | - | - | Direct |
| May 19, 2025 | TLSI TriSalus Life Sciences, Inc. | Award(A) | 28,455 | $5.18 | $147,397 | Direct |
| May 19, 2025 | TLSI TriSalus Life Sciences, Inc. | Sale(S) | 8,704 | $5.18 | $45,087 | Direct |
| Feb 18, 2025 | TLSI TriSalus Life Sciences, Inc. | Award(A) | 14,481 | - | - | Direct |
| Jan 27, 2025 | TLSI TriSalus Life Sciences, Inc. | Award(A) | 10,625 | - | $0 | Direct |
1-9 of 9 transactions
About Stevens Jennifer
Stevens Jennifer (SEC CIK 0001982621) files insider reports with the SEC as Chief Regulatory Officer of TriSalus Life Sciences, Inc. (TLSI).
Signal8 holds 6 ownership filings by Stevens Jennifer, all Form 4s, filed between Jan 29, 2025 and Oct 7, 2026. Those filings report 9 transactions, from Jan 27, 2025 to Oct 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Stevens Jennifer's filings is in WESTMINSTER, CO.
Recent filings by Stevens Jennifer
- Oct 5, 2026: Open-market sale of TLSI shares (Form 4, code S).
- Mar 16, 2026: Open-market sale of TLSI shares (Form 4, code S).
- Mar 12, 2026: Open-market sale of TLSI shares (Form 4, code S).
- Mar 11, 2026: Open-market sale of TLSI shares (Form 4, code S).
- Nov 24, 2025: Grant or award of TLSI shares (Form 4, code A).
Other insiders filing for TriSalus Life Sciences, Inc. (TLSI)
- Cox Bryan F., Chief of Research
- Marshak Richard, Chief Commercial Officer
- Szela Mary T, CEO and President
- Patience David, Chief Financial Officer
- Marshall Richard Henry, Chief Medical Officer
- Wahlstrom Mats, Director